Ivonescimab shows improved overall survival in Phase III HARMONi trial.
Updated analysis of the global Phase III HARMONi trial demonstrates statistically significant and consistent overall survival benefits for ivonescimab plus chemotherapy in both Western and Asian NSCLC patients.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day